Performance of in silico analysis in predicting the effect of non-synonymous variants in inherited steroid metabolic diseases.
Unclassified genetic variants are commonly encountered in molecular diagnostic service. In silico analyses using web-based predictive programs may provide information on the nature of the genetic variants, and help to prioritize novel variants for in vitro functional characterization. The objective of this study was to compare the performance of three such programs in genes related to steroid metabolism. The effects of non-synonymous benign and pathogenic sequence variants in the CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP19A1, CYP21A2, DHCR7, HSD3B2, HSD11B2, HSD17B3, POR, and SRD5A2 genes listed in the Human Gene Mutation Database and dbSNP were tested by SIFT, PolyPhen-2 and PON-P. Their concordance, sensitivity, specificity, positive and negative predictive values and accuracy were assessed, using the reported phenotype and the in vitro functional data as gold standards. 797 sequence variants were tested. SIFT and PolyPhen-2 had high concordance, with PolyPhen-2 being slightly superior to SIFT in all assessments. PON-P behaved differently, with one-third of the variants unclassified. SIFT and PolyPhen-2 behaved similarly while PON-P behaved differently in predicting pathogenicity in genes related to steroid metabolism. Molecular pathologists should verify the performance of these programs before considering them in clinical decision making, and be aware that these programmes cannot replace in vitro function studies. Clinicians and patients should also be informed about the limitations of genetic testing, particularly when a novel variant is encountered.